Sino Biopharmaceutical (HKG:1177) said the Phase III study of Benmelstobart combined with two other drugs for advanced squamous non-small cell lung cancer achieved positive results, allowing it to obtain China's consent to file a marketing application.
The combination of Benmelstobart Injection with chemotherapy and Anlotinib Hydrochloride Capsules was tested against Tislelizumab Injection with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC).
The Independent Data Monitoring Committee determined that the primary study endpoint of progression-free survival (PFS) has met the protocol's predefined superiority threshold, Sino Biopharm said.
The Chinese drugmaker said it will submit the marketing application "in the near future," according to a Friday filing with the Hong Kong bourse.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。